Therapeutics or Clinical Pharmacology (project 1) – Renal Medicine/Cardiology
- Jon Barratt
- Nigel Brunskill
- James Burton
Chronic kidney disease (CKD) affects in excess of 700 million people with a global prevalence of 9·1% and since 1990, the CKD prevalence has increased by 29·3%. Treatment of CKD is severely limited with few disease-modifying drugs and the most effective treatments being generic, targeting blood pressure control, concomitant diabetes and cardiovascular disease.
The renal group within the University is internationally renowned for delivery of investigator initiated clinical studies of new therapeutics to treat CKD and delivers a bench to bedside approach to novel therapeutic targeting. The group is fully integrated with the NIHR BRC, the Leicester Precision Medicine Institute and the BHF Accelerator. Expertise includes immunologically mediated kidney disease (Barratt), proteinuric CKD (Brunskill), cardiovascular disease in CKD (Burton) and cardiovascular imaging (Graham-Brown).
All senior investigators have held personal awards including NIHR Clinician Scientists (Barratt and Burton), Welcome Trust Senior Fellowship (Brunskill) and NIHR Clinical Lectureships (Burton/Graham-Brown) and have extensive experience in supervising and mentoring trainees on the Integrated Academic Training Pathway.
The ACF will have the opportunity to join one of our experimental medicine studies evaluating the mechanism of action of one of a number of different drugs currently being evaluated by the group. Depending on their own interests there is the option to undertake training in basic laboratory techniques including evaluation of transcriptomic and proteomic changes in post treatment kidney biopsy tissue or alternatively train in evaluation of the cardiovascular response to drugs targeting glomerular hypertension using non-invasive imaging and high throughput proteomic profiling.